B-CLEAR® only in vitro method to predict in vivo liver disposition

RALEIGH, N.C., U.S.A. (Oct 18, 2006)

Qualyst today announced that Covance Laboratories, Inc., one of the world's largest and most comprehensive drug development services companies, has licensed the use of Qualyst’s proprietary, patented B-CLEAR® system to provide its pharmaceutical and biotechnology sponsors with pharmacokinetic services. Terms were not disclosed.

B-CLEAR® is a sandwich-cultured hepatocyte system for the in vitro assessment and in vivo prediction of critical pharmacokinetic properties, including hepatobiliary disposition, hepatic uptake, hepatic accumulation, biliary clearance and drug transport. B-CLEAR® offers research organizations the ability to generate physiologically-relevant data and enable decision making in critical areas related to hepatic transport and adverse drug interactions, helping to avoid costly drug development challenges, and enabling better prediction of bioavailability, pharmacokinetics, species-specific drug dosing and candidate selection.

“Covance’s decision to license B-CLEAR® will allow researchers across the biopharmaceutical industry to gain value from B-CLEAR® profiling while accessing Covance’s catalog of complementary services and expertise,” says Scott Neuville, Qualyst president and CEO.

About Qualyst, Inc.
Qualyst commercializes novel and proprietary ADMET products for drug discovery and development. Qualystís products allow pharmaceutical and biotechnology researchers to make faster, better decisions regarding drug candidate compounds, saving valuable time and research dollars in the process. Qualyst, Inc. was founded on discoveries from breakthrough research at the University of North Carolina at Chapel Hill in 2001. For additional information, please refer to the company's web site at www.Qualyst.com or call 919-313-6500.

QUALYST CONTACT:

Ian J. Mehr
Vice President, Business Development
Qualyst, Inc.
(919)313-6507
info[AT]qualyst[DOT]com
www.Qualyst.com